Tan Yuan, Salkhordeh Mahmoud, Murray Aidan B P, Souza-Moreira Luciana, Stewart Duncan J, Mei Shirley H J
Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Front Bioeng Biotechnol. 2024 Aug 1;12:1412811. doi: 10.3389/fbioe.2024.1412811. eCollection 2024.
Cryopreservation is a critical process of cell products for achieving a commercial viability through wide scale adoption. By preserving cells in a lower temperature, cryopreservation enables a product to be off-the-shelf and ready for infusion. An optimized cryopreservation strategy can maintain the viability, phenotype, and potency of thawed mesenchymal stromal/stem cells (MSCs) while being regulatory compliant. We compared three clinical-ready formulations with one research cryopreservation solutions and evaluated key quality parameters of post thawed MSCs.
MSCs were cryopreserved at 3, 6, and 9 million cells/mL (M/mL) in four different cryopreservation solutions: NutriFreez (10% dimethyl sulfoxide [DMSO]), Plasmalyte A (PLA)/5% human albumin (HA)/10% DMSO (PHD10), CryoStor CS5 (5% DMSO), and CryoStor CS10 (10% DMSO). To establish post thaw viability, cells were evaluated with no dilution of DMSO (from 3 M/mL), 1:1 dilution (from 6 M/mL), or 1:2 dilution (from 9 M/mL) with PLA/5% HA, to achieve uniform concentration at 3 M/mL. Cell viability was measured at 0-, 2-, 4-, and 6-h post thaw with Trypan blue exclusion and Annexin V/PI staining. Dilution (1:2) of final cell products from 9M/mL resulted in an improvement of cell viability over 6 h but showed a trend of decreased recovery. MSCs cryopreserved in solutions with 10% DMSO displayed comparable viabilities and recoveries up to 6 h after thawing, whereas a decreasing trend was noted in cell viability and recovery with CS5. Cells from all groups exhibited surface marker characteristics of MSCs. We further evaluated cell proliferation after 6-day recovery in culture. While cells cryopreserved in NutriFreez and PHD10 presented similar cell growth post thaw, MSCs cryopreserved in CS5 and CS10 at 3 M/mL and 6M/mL showed 10-fold less proliferative capacity. No significant differences were observed between MSCs cryopreserved in NutriFreez and PHD10 in their potency to inhibit T cell proliferation and improve monocytic phagocytosis.
MSCs can be cryopreserved up to 9 M/mL without losing notable viability and recovery, while exhibiting comparable post thaw potency with NutriFreez and PHD10. These results highlight the importance of key parameter testing for selecting the optimal cryopreservation solution for MSC-based therapy.
冷冻保存是细胞产品实现广泛商业应用可行性的关键过程。通过在低温下保存细胞,冷冻保存使产品能够随时取用并准备好进行输注。优化的冷冻保存策略可以在符合监管要求的同时,维持解冻后间充质基质/干细胞(MSC)的活力、表型和效能。我们比较了三种临床可用配方与一种研究用冷冻保存溶液,并评估了解冻后MSC的关键质量参数。
将MSC以300万、600万和900万个细胞/毫升(M/mL)的浓度保存在四种不同的冷冻保存溶液中:NutriFreez(10%二甲基亚砜 [DMSO])、Plasmalyte A(PLA)/5%人白蛋白(HA)/10%DMSO(PHD10)、CryoStor CS5(5%DMSO)和CryoStor CS10(10%DMSO)。为了确定解冻后的活力,将细胞用PLA/5%HA不稀释DMSO(来自3M/mL)、1:1稀释(来自6M/mL)或1:2稀释(来自9M/mL)进行评估,以在3M/mL达到均匀浓度。在解冻后0、2、4和6小时用台盼蓝排斥法和膜联蛋白V/碘化丙啶染色测量细胞活力。将最终细胞产品从9M/mL稀释(1:2)导致6小时内细胞活力有所改善,但显示出回收率下降的趋势。保存在含10%DMSO溶液中的MSC在解冻后6小时内显示出相当的活力和回收率,而CS5组的细胞活力和回收率则呈下降趋势。所有组的细胞均表现出MSC的表面标志物特征。我们进一步评估了培养6天恢复后的细胞增殖情况。虽然保存在NutriFreez和PHD10中的细胞解冻后呈现相似的细胞生长,但保存在CS5和CS10中3M/mL和6M/mL浓度的MSC增殖能力低10倍。保存在NutriFreez和PHD10中的MSC在抑制T细胞增殖和改善单核细胞吞噬作用的效能方面未观察到显著差异。
MSC可以在高达9M/mL的浓度下进行冷冻保存,而不会显著丧失活力和回收率,同时与NutriFreez和PHD10相比,解冻后具有相当的效能。这些结果突出了关键参数测试对于为基于MSC的治疗选择最佳冷冻保存溶液的重要性。